Dana M. Chase, MD, discusses the effect of the frontline dostarlimab plus chemotherapy on the recurrent endometrial cancer landscape.
Bridging the Gaps in Lung Cancer
Triparna Sen, PhD, discusses the role of immunotherapy for the treatment of patients with small cell lung cancer.
Narjust Florez, MD discusses the importance of establishing expert consensus in the evolving lung cancer treatment landscape in 2025.
Jorge Nieva, MD, discusses matched-adjusted indirect comparison data evaluating crizotinib vs alectinib, brigatinib, and lorlatinib in ALK-positive NSCLC.
Sandip P. Patel, MD, discusses toxicities associated with the use of immunotherapy-based combination regimens in patients with advanced NSCLC.
Elaine Shum, MD, discusses questions that remain regarding the first-line treatment paradigm for patients with EGFR-mutant non–small cell lung cancer.
Jessica Donington, MD, MSCR, discusses how updated data with perioperative nivolumab in NSCLC may affect future surgical decision-making.
Advertisement
Advertisement
Trending on OncLive
1
Targeted Therapies, ADCs, and Oral SERD Combos Expand Treatment Possibilities Across Breast Cancer Settings
2
Head and Neck Oncologists Highlight Practice-Informing Research From ASCO 2026
3
Dr Galsky on the Current Roles of Biomarkers in Bladder Cancer
4
Sonrotoclax Plus Zanubrutinib Yields High Undetectable MRD Rates in Treatment-Naive CLL/SLL
5